The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine.
Phoenix will soon be the home of the Center for Advanced Molecular and Immunological Therapies, a new University of Arizona Health Sciences center focused on developing biological therapies that stimulate or suppress the immune system to fight disease.
Researchers and physician-scientists are increasingly using precision medicine to develop new cell- and gene-based therapeutical options for diseases, building on the idea that the most effective defense against health issues is the body’s natural immune system. The Center for Advanced Molecular and Immunological Therapies, or CAMI, will be a hub to advance knowledge of the immunology of cancers, infectious diseases and autoimmune conditions to develop novel strategies for the diagnosis, prevention and treatment of diseases.
“Our expertise in basic science, translational medicine and investigator-initiated clinical trials will allow the University of Arizona Health Sciences to lead the nation in advanced immunotherapies research,” said Michael D. Dake, MD, University of Arizona Health Sciences senior vice president. “We believe the Phoenix Bioscience Core is the perfect location to allow us to bring together world-class faculty, clinical researchers and internationally recognized thought leaders to catalyze the next generation of precision health care treatments.”
CAMI will serve as the anchor for an innovation district that aims to differentiate Phoenix from other emerging life sciences hubs, establishing the Phoenix Bioscience Core as a center of cell and gene therapy research, startup activity and corporate engagement.
The center will have four areas of research focus: cancer, infectious diseases, autoimmune diseases and real-time immune system monitoring. Immunotherapy is one of the most promising approaches to cancer treatment, as it has the potential to sidestep the effects of therapies that can compromise patients’ long-term health and wellness. Classic immunotherapies such as vaccines already are being tested for some types of cancers, while the COVID-19 pandemic has highlighted vaccines’ continued importance in a world threatened by emerging pathogens.
Other examples of potential research include identifying biomarkers for response to immunotherapy that may help determine the precise drugs to fight specific cancers in individual patients, understanding individual immune responses to autoimmune diseases such as lupus, rheumatoid arthritis or Crohn’s disease, and creating ways to analyze immune health at the cellular level to identify how individuals might respond to a disease and to predict their health outcomes.
The research will take place in connected buildings that are being designed to include laboratories to support translational research, clinical research space and startup incubator space to create a synergistic environment for commercialization opportunities. Student education will be prioritized in learning spaces dedicated to academic programs that will allow CAMI faculty and researchers to mentor and train the next generation of scientists.
Using New Economy Initiative funding provided to the University of Arizona and allocated to UArizona Health Sciences, CAMI is being developed under the guidance of a 17-member advisory council of leaders from academic research, biomedical and health care industries, government organizations and corporations across the state. The center’s location in Phoenix is expected to facilitate strong connections with partners such as Arizona State University, Northern Arizona University, the Mayo Clinic and the Translational Genomics Research Institute, while boosting the local economy in the process.